Bryn Pharma

Executive Summary

Bryn Pharma is a privately-held biopharmaceutical company based in Raleigh, North Carolina, founded in 2017 with a focus on developing a novel intranasal epinephrine delivery system for the emergency treatment of anaphylaxis. The company aims to address the limitations of existing auto-injectors by providing a more convenient, portable, and needle-free alternative. Given the rising prevalence of severe allergies and the need for easy-to-administer rescue therapies, Bryn Pharma's product candidate holds significant market potential. However, as a private company with undisclosed funding and development stage, the near-term visibility is limited. The company is likely in preclinical or early clinical stages, and its success hinges on demonstrating bioequivalence and safety in clinical trials, securing regulatory approvals, and establishing manufacturing capabilities. The competitive landscape includes established auto-injectors (e.g., EpiPen) and emerging intranasal epinephrine products (e.g., from ARS Pharmaceuticals), so Bryn Pharma must differentiate on performance, convenience, and cost.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 1 clinical trial for intranasal epinephrine50% success
• Q3 2026FDA meeting feedback on development pathway65% success
• TBDPartnership or licensing deal with larger pharmaceutical company30% success